SEC 13F Intelligence

Managers / Q4 2020 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$1.4B
Q4 2020
Positions
97
Filings on Record
30
2019–present window
Filed
Feb 12, 2021
original filing

Summary

Sectoral Asset Management Inc reported $1.4B in U.S.-listed holdings across 97 positions for Q4 2020.

Its largest position, AVIR, represents 4.4% of the portfolio.

Compared with Q3 2020, the fund opened 25 new positions and exited 16.

Portfolio Metrics

Turnover
+22.7%
vs prior filed quarter
Top-10 Concentration
+29.3%
share of reported value
Largest Position
+4.4%
Atea Pharmaceuticals
New / Exited
25 / 16
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.8%Other: 12.1%ADR: 0.1%
  • Common Stock · 87.8% · $1.2B
  • Other · 12.1% · $171M
  • ADR · 0.1% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AVIRATEA PHARMACEUTICALS INCNEW+1.49M1.49M+$62M$62M
MRVIMARAVAI LIFESCIENCES HLDGS INEW+978.6K978.6K+$27M$27M
REPLREPLIMUNE GROUP INCNEW+667.7K667.7K+$25M$25M
CERTCERTARA INCNEW+605.9K605.9K+$20M$20M
RCKTROCKET PHARMACEUTICALS INCNEW+367.4K367.4K+$20M$20M
ZBHZIMMER BIOMET HOLDINGS INCNEW+121.0K121.0K+$19M$19M
MRTXEURMIRATI THERAPEUTICS INCNEW+73.6K73.6K+$16M$16M
OAK STR HEALTH INCNEW+250.0K250.0K+$15M$15M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AVIRATEA PHARMACEUTICALS INChistory →COM4.39%$62M1.49M
2ARVNARVINAS INChistory →COM3.18%$45M532.1K
3TNDMTANDEM DIABETES CARE INChistory →COM NEW3.18%$45M471.8K
4TDOCTELADOC HEALTH INChistory →COM2.96%$42M209.9K
5LABORATORY CORP AMER HLDGSCOM NEW2.90%$41M202.2K
6PTCTPTC THERAPEUTICS INChistory →COM2.60%$37M604.0K
7EX9EXELIXIS INChistory →COM2.55%$36M1.80M
8ATRCATRICURE INChistory →COM2.53%$36M644.2K
9TFXTELEFLEX INCORPORATEDhistory →COM2.50%$35M86.2K
10AM6AMICUS THERAPEUTICS INChistory →COM2.50%$35M1.53M
11ACADACADIA PHARMACEUTICALS INChistory →COM2.47%$35M654.4K
12PPD INCCOM2.36%$33M977.2K
13EVHEVOLENT HEALTH INChistory →CL A2.31%$33M2.05M
14TURNING POINT THERAPEUTICS ICOM2.21%$31M257.4K
15AFIBACUTUS MED INChistory →COM1.99%$28M982.2K
16RCMEURR1 RCM INChistory →COM1.99%$28M1.17M
17DCPHEURDECIPHERA PHARMACEUTICALS INhistory →COM1.97%$28M488.8K
18MRVIMARAVAI LIFESCIENCES HLDGS Ihistory →COM CL A1.93%$27M978.6K
19REPLREPLIMUNE GROUP INChistory →COM1.80%$25M667.7K
20IRTCIRHYTHM TECHNOLOGIES INChistory →COM1.78%$25M106.6K
21SILKUSDSILK RD MED INChistory →COM1.77%$25M399.5K
22NVV1NOVAVAX INChistory →COM NEW1.76%$25M223.3K
23AFWALIGN TECHNOLOGY INChistory →COM1.74%$25M46.1K
24ARNAEURARENA PHARMACEUTICALS INChistory →COM NEW1.73%$25M320.1K
25RGENREPLIGEN CORPhistory →COM1.68%$24M124.2K
26IDXXIDEXX LABS INChistory →COM1.67%$24M47.4K
27RCUSARCUS BIOSCIENCES INChistory →COM USD1.58%$22M861.2K
28CERTCERTARA INChistory →COM1.44%$20M605.9K
29RCKTROCKET PHARMACEUTICALS INChistory →COM1.42%$20M367.4K
30ZBHZIMMER BIOMET HOLDINGS INChistory →COM1.31%$19M121.0K
31AMERICAN WELL CORPCL A1.29%$18M724.1K
32PRAHPRA HEALTH SCIENCES INChistory →COM USD1.21%$17M136.8K
33MRTXEURMIRATI THERAPEUTICS INChistory →COM1.14%$16M73.6K
34DC4DEXCOM INChistory →COM1.11%$16M42.5K
35RVMDREVOLUTION MEDICINES INChistory →COM1.09%$15M389.0K
36CNCCENTENE CORP DELhistory →COM1.09%$15M256.5K
372655787DBLUEPRINT MEDICINES CORPhistory →COM1.08%$15M136.5K
38OAK STR HEALTH INCCOM1.08%$15M250.0K
39SRPTSAREPTA THERAPEUTICS INChistory →COM1.04%$15M86.6K
40RMERESMED INChistory →COM0.99%$14M66.3K
41ALNYALNYLAM PHARMACUETICALS INChistory →COM0.99%$14M108.3K
42ALXNALEXION PHARMACEUTICALS INChistory →COM0.97%$14M88.0K
43MRNAMODERNA INChistory →COM0.93%$13M126.3K
44FREELINE THERAPEUTICS HLDGSSPONSORED ADS0.85%$12M657.5K
45JNJJOHNSON & JOHNSONhistory →COM0.83%$12M74.5K
46HO1HOLOGIC INChistory →COM0.81%$12M158.3K
47PODDINSULET CORPhistory →COM0.77%$11M42.7K
48SIGILON THERAPEUTICS INCCOM0.76%$11M225.0K
49TGTXTG THERAPEUTICS INChistory →COM0.76%$11M206.5K
50ABBVABBVIE INChistory →COM0.72%$10M95.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.